Application
A. Western blot analysis on Hela cell lysate using anti- NF-kappaB p65 RabMAb (Cat. #AJ1537a).Application
B. Immunohistochemical analysis of paraffin-embedded human Breast carcinoma using anti-NF-kappaB p65 RabMAb (Cat. #AJ1537a).Application
C. Immunofluorescent staining of HeLa cells using anti anti-NF-kappaB p65 RabMAb (Cat. #AJ1537a)| Product Name | NF-kappaB Antibody (p65 subunit) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | RELA, NFKB3, Transcription factor p65, Nuclear factor NF-kappa-B p65 subunit |
| Clonality | Monoclonal |
|---|---|
| Clone Number | E379 |
| Host Species | Rabbit |
| Tested Applications | WBIHCIF |
| WB:1:500 IHC |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | NFKB3 |
|---|---|
| Alternative Names | RELA NFKB3 Transcription factor p65 Nuclear factor NF-kappa-B p65 subunit |
| Molecular Weight(MW) | 60219 Da |
| Function | NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1 |
| Tissue Specificity | A synthetic peptide corresponding to residues near the C-terminus of human nuclear factor NF-kappa-B p65 subunit was used as immunogen. |
| Cellular Localization | Nucleus. Cytoplasm. Note=Colocalized with DDX1 in the nucleus upon TNF-alpha induction (By similarity) Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 in the nucleus after LPS stimulation |
| Entrez Gene | 5970 |
|---|
Application
A. Western blot analysis on Hela cell lysate using anti- NF-kappaB p65 RabMAb (Cat. #AJ1537a).
Application
B. Immunohistochemical analysis of paraffin-embedded human Breast carcinoma using anti-NF-kappaB p65 RabMAb (Cat. #AJ1537a).
Application
C. Immunofluorescent staining of HeLa cells using anti anti-NF-kappaB p65 RabMAb (Cat. #AJ1537a)| Application Notes | WB:1:500 IHC |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. |
